In this CME Outfitters chapter series, expert faculty will discuss strategies for identifying disparities when caring for persons of color living with HIV, communicating about HIV risk with patients from diverse backgrounds, and develop long-term, personalized care plans that include rapid initiation of antiretroviral therapies (ARTs) and support for treatment adherence for PLWH.
In this CME Outfitters Live Q&A, expert faculty and a patient advocate will answer questions on clinical experience, study information, updates to guidelines, resources, and how to integrate sensitive and respectful discussions about anal cancer risk, prevention, and screening into everyday clinical workflows to improve outcomes for patients at high risk for anal cancer.
In this CMEO recorded webcast, expert faculty will present and discuss advances in non-factor therapies for hemophilia, including advancements in laboratory and monitoring practices and how to use shared decision-making (SDM) with patients to design individualized care plans that incorporate non-factor replacement therapies into treatment.
In this CME Outfitters recorded webcast, expert faculty will discuss the role of FcRn in the pathogenesis of gMG, evaluate the safety and efficacy of FcRn antagonists for the treatment of gMG, and provide expert guidance on how to identify patients with gMG who may be appropriate candidates for treatment with FcRn antagonists. Finally, they will model development of optimized and individualized treatment plans for patients with gMG receiving FcRn antagonists, providing learners with key skills to bring back to clinical practice.
In this CME Outfitters recorded symposium, leading experts will explore:
✅ Early, guideline-based diagnosis to improve patient outcomes
✅ The latest efficacy and safety data on current and emerging therapies, including oral treatments
✅ Individualized care strategies that consider patient needs, comorbidities, and barriers to adherence
Stay ahead of the curve with cutting-edge insights to enhance patient care and optimize long-term management of acromegaly.
In this CME Outfitters recorded symposium, faculty will examine the role of pro-inflammatory cytokines in the pathogenesis of IBD, discern differences in IL-23 binding among IL-23p19–targeted therapies, assess the safety and efficacy of IL-23p19–targeted therapies for the treatment of IBD, and explore when to incorporate IL-23p19–targeted therapies into the management of patients with IBD.
Miguel Regueiro earned his bachelor’s degree at the University of Pennsylvania, his medical degree at Drexel (Hahnemann) University and completed his internal medicine internship, residency, and clinical and research fellowship training in gastroenterology at Harvard Medical School’s Beth Israel Hospital.
Dr. Regueiro was Professor of Medicine and Clinical and Translational Science at the University of Pittsburgh School of Medicine from 2000 to 2018. There he served as the IBD Clinical Medical Director, Senior Medical Lead of Specialty Medical Homes, was Professor with Tenure, and honored as the UPMC Endowed Chair for Patient Centered Care in Inflammatory Bowel Diseases.
Dr. Regueiro is currently the Chair of the Department of Gastroenterology and Hepatology and Chair of the Digestive Disease and Surgery Institute at Cleveland Clinic in Ohio. He serves as Medical Co- Chair of Digestive Disease and Surgical Institute Research Governance committee and is Professor of Medicine at the Lerner College of Medicine, Cleveland Clinic.
Dr. Regueiro’s main clinical and research interest is Inflammatory Bowel Diseases with a focus on the natural course of these diseases and postoperative prevention of Crohn’s disease. Recently, he has been involved in transformative medicine initiatives and developing new models of healthcare, including the first-of-its kind specialty medical home for IBD. Dr. Regueiro is investigating alternative models of care in population-based health that integrates patients, payers, providers, pharmaceutical industry, and other facets of healthcare delivery around these novel programs.